Heterogeneous progression of AT(N) biomarkers in data-driven subtypes of Alzheimer's disease.
- 1Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- 2Department of Nursing, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Abstract
Background
Alzheimer's disease (AD) exhibits substantial heterogeneity in brain atrophy patterns and progression rates. Data-driven subtyping based on the Subtype and Stage Inference (SuStaIn) model has identified distinct MRI-derived subtypes, but the longitudinal dynamics of these subtypes within the AT(N) framework remain unknown.Methods
This study included 1,576 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with at least two visits. SuStaIn was applied to volumetric measurements of 11 brain regions to identify imaging-based subtypes. Within each subtype, we fitted a Bayesian latent time longitudinal joint mixed-effects model incorporating six biomarkers: amyloid PET (A), CSF p-tau (T), hippocampal volume, cingulate volume, thalamic volume (N), and ADAS-Cog13 (X), with APOE ε4 as a covariate.Results
The three subtypes exhibited distinctly different longitudinal patterns. Subtype 1 showed early elevation of amyloid, followed by a sharp decline in hippocampal volume, which was tightly coupled with cognitive deterioration. Subtype 2 featured early involvement of cortical regions such as the cingulate cortex, with hippocampal changes occurring at a similar timing to Subtype 1 but accompanied by earlier cortical and thalamic involvement. Subtype 3 exhibited early rapid hippocampal atrophy that later plateaued, and demonstrated the strongest hippocampus-cognition coupling. The association of APOE ε4 with biomarker trajectories was subtype-dependent: its effect estimates were largest for amyloid and p-tau in Subtype 1, whereas in Subtype 3 the effect estimates were significant for nearly all biomarkers, with the largest estimate for cognition.Conclusion
This study demonstrates that AD subtypes defined by spatial atrophy patterns also differ fundamentally in temporal biomarker dynamics and APOE ε4 association, supporting subtype-stratified modeling of disease progression.
Related
- Dynamic remodeling of microglial responses in Alzheimer's disease: heterogeneous states, spatiotemporal progression, and immunometabolic dysregulation.
- Multi-omics profiling uncovers diagnostic biomarker panel, progression-associated subtypes, and prognostic signature in pediatric mitochondrial disease
- A neurocognitive speech taxonomy for voice biomarkers of Alzheimer's disease
- No evidence that serum metabolite slopes improve held-out prediction of clinical progression in the Alzheimer’s disease neuroimaging initiative
- Sex‐specific brain reserve and progression from mild cognitive impairment to Alzheimer's disease dementia
BibTeX
@article{teng2026heterogeneous,
title = {{Heterogeneous progression of AT(N) biomarkers in data-driven subtypes of Alzheimer's disease.}},
author = {Zhiwei Teng and Mengyun Hu and Zhongwei Zhang and Mingqi Zhou and Ping Yin and Alzheimer’s Disease Neuroimaging Initiative},
journal = {Frontiers in aging neuroscience},
year = {2026},
month = oct,
doi = {10.3389/fnagi.2026.1902282},
url = {https://europepmc.org/article/MED/42948157},
note = {CC BY},
}
RIS
TY - JOUR
TI - Heterogeneous progression of AT(N) biomarkers in data-driven subtypes of Alzheimer's disease.
AU - Zhiwei Teng
AU - Mengyun Hu
AU - Zhongwei Zhang
AU - Mingqi Zhou
AU - Ping Yin
AU - Alzheimer’s Disease Neuroimaging Initiative
PY - 2026
DA - 2026/10/13
JO - Frontiers in aging neuroscience
DO - 10.3389/fnagi.2026.1902282
UR - https://europepmc.org/article/MED/42948157
AB - Background Alzheimer's disease (AD) exhibits substantial heterogeneity in brain atrophy patterns and progression rates. Data-driven subtyping based on the Subtype and Stage Inference (SuStaIn) model has identified distinct MRI-derived subtypes, but the longitudinal dynamics of these subtypes within the AT(N) framework remain unknown.Methods This study included 1,576 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with at least two visits. SuStaIn was applied to volumetric measurements of 11 brain regions to identify imaging-based subtypes. Within each subtype, we fitted a Bayesian latent time longitudinal joint mixed-effects model incorporating six biomarkers: amyloid PET (A), CSF p-tau (T), hippocampal volume, cingulate volume, thalamic volume (N), and ADAS-Cog13 (X), with APOE ε4 as a covariate.Results The three subtypes exhibited distinctly different longitudinal patterns. Subtype 1 showed early elevation of amyloid, followed by a sharp decline in hippocampal volume, which was tightly coupled with cognitive deterioration. Subtype 2 featured early involvement of cortical regions such as the cingulate cortex, with hippocampal changes occurring at a similar timing to Subtype 1 but accompanied by earlier cortical and thalamic involvement. Subtype 3 exhibited early rapid hippocampal atrophy that later plateaued, and demonstrated the strongest hippocampus-cognition coupling. The association of APOE ε4 with biomarker trajectories was subtype-dependent: its effect estimates were largest for amyloid and p-tau in Subtype 1, whereas in Subtype 3 the effect estimates were significant for nearly all biomarkers, with the largest estimate for cognition.Conclusion This study demonstrates that AD subtypes defined by spatial atrophy patterns also differ fundamentally in temporal biomarker dynamics and APOE ε4 association, supporting subtype-stratified modeling of disease progression.
SN - 1663-4365
ER -